- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
Authors
Keywords
-
Journal
Biomarker Research
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-02-18
DOI
10.1186/s40364-021-00264-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer
- (2020) Yuxiang Li et al. CELLULAR IMMUNOLOGY
- Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
- (2020) Fabio Nicolini et al. Frontiers in Oncology
- Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability
- (2020) Sonia Guedan et al. JOURNAL OF CLINICAL INVESTIGATION
- Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma.
- (2020) Christina M. Annunziata et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells
- (2020) Elham Masoumi et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Human chimeric antigen receptor macrophages for cancer immunotherapy
- (2020) Michael Klichinsky et al. NATURE BIOTECHNOLOGY
- Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action
- (2020) Yukinori Take et al. Frontiers in Immunology
- ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743
- (2020) P. Baas et al. Journal of Thoracic Oncology
- Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent.
- (2019) Prasad S. Adusumilli et al. JOURNAL OF CLINICAL ONCOLOGY
- Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma
- (2019) Iris C. Salaroglio et al. Journal of Thoracic Oncology
- Phase I study of lentiviral-transduced chimeric antigen receptor modified T cells recognizing mesothelin in advanced solid cancers
- (2019) Andrew R. Haas et al. MOLECULAR THERAPY
- Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor
- (2019) Zhiwei Zhang et al. Cell Death & Disease
- The tumor vasculature an attractive CAR T cell target in solid tumors
- (2019) Parvin Akbari et al. ANGIOGENESIS
- 1174OPembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies
- (2019) L A Diaz et al. ANNALS OF ONCOLOGY
- Emerging therapies in malignant pleural mesothelioma
- (2019) Marika Cinausero et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
- (2019) Gerard J. Chu et al. Frontiers in Oncology
- Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma
- (2018) Jorien Minnema-Luiting et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines
- (2018) Edmund K. Moon et al. OncoImmunology
- Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function
- (2018) Alexander I. Salter et al. Science Signaling
- CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions
- (2018) Wanghong Hu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Programmed cell death protein 1 activation preferentially inhibits CD28.CAR–T cells
- (2018) Sergey N. Zolov et al. CYTOTHERAPY
- Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
- (2018) Judith Feucht et al. NATURE MEDICINE
- Immunotherapy strategies for mesothelioma – the role of tumor specific neoantigens in a new era of precision medicine
- (2018) Linda Ye et al. Expert Review of Respiratory Medicine
- T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy
- (2017) Robert Sackstein et al. LABORATORY INVESTIGATION
- CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy
- (2017) Nan Chen et al. OncoImmunology
- CAR T-cell immunotherapy of MET-expressing malignant mesothelioma
- (2017) Thivyan Thayaparan et al. OncoImmunology
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
- (2016) Xiaojun Liu et al. CANCER RESEARCH
- Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy
- (2016) Mark O'Hara et al. Immunotherapy
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization
- (2016) K. Newick et al. Cancer Immunology Research
- CAR therapy: the CD19 paradigm
- (2015) Michel Sadelain JOURNAL OF CLINICAL INVESTIGATION
- The pharmacology of second-generation chimeric antigen receptors
- (2015) Sjoukje J. C. van der Stegen et al. NATURE REVIEWS DRUG DISCOVERY
- Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
- (2015) A. Morello et al. Cancer Discovery
- New High Affinity Monoclonal Antibodies Recognize Non-Overlapping Epitopes On Mesothelin For Monitoring And Treating Mesothelioma
- (2015) Yi-Fan Zhang et al. Scientific Reports
- Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
- (2015) E. Wang et al. Cancer Immunology Research
- Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy
- (2014) I. Pastan et al. CANCER RESEARCH
- Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma
- (2014) Robin Cornelissen et al. PLoS One
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
- (2014) P. S. Adusumilli et al. Science Translational Medicine
- Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells
- (2014) Rachel E Beard et al. Journal for ImmunoTherapy of Cancer
- The Worldwide Pandemic of Asbestos-Related Diseases
- (2013) Leslie Stayner et al. Annual Review of Public Health
- The Role of Mesothelin in Tumor Progression and Targeted Therapy
- (2013) Zhewei Tang et al. Anti-Cancer Agents in Medicinal Chemistry
- Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases
- (2013) M. J. Riese et al. CANCER RESEARCH
- Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
- (2013) Douglas W Henderson et al. JOURNAL OF CLINICAL PATHOLOGY
- Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells
- (2013) Petra C Schuberth et al. Journal of Translational Medicine
- Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
- (2013) G. L. Beatty et al. Cancer Immunology Research
- T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
- (2013) M. V. Maus et al. Cancer Immunology Research
- Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group
- (2012) Aliya N. Husain et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)
- (2012) Ulf Petrausch et al. BMC CANCER
- Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients
- (2012) E. L. Servais et al. CLINICAL CANCER RESEARCH
- Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma
- (2012) Saly Al-Taei et al. LUNG CANCER
- Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
- (2011) E. K. Moon et al. CLINICAL CANCER RESEARCH
- Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor
- (2011) Evripidis Lanitis et al. MOLECULAR THERAPY
- Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
- (2011) Antonio Di Stasi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells
- (2011) S. Amarnath et al. Science Translational Medicine
- CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
- (2010) Noriyuki Yamada et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor
- (2010) Y. Zhao et al. CANCER RESEARCH
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
- (2009) C. Carpenito et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mesothelin targeted cancer immunotherapy
- (2007) Raffit Hassan et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started